Pyrimidine inhibitors synergize with nucleoside analogues to block SARS-CoV-2
Schultz DC, Johnson RM, Ayyanathan K, Miller J, Whig K, Kamalia B, Dittmar M, Weston S, Hammond HL, Dillen C, Ardanuy J, Taylor L, Lee JS, Li M, Lee E, Shoffler C, Petucci C, Constant S, Ferrer M, Thaiss CA, Frieman MB, Cherry S. Nature. 2022 Feb 7. doi: 10.1038/s41586-022-04482-x. Online ahead of print.
Summary
Research led by Sara Cherry, PhD, of Pathology and Laboratory Medicine, with David Schultz, PhD, technical director of the High-Throughput Screening Core, identified a powerful combination of antivirals to treat COVID-19. The combination of remdesivir or molnupiravir with the experimental drug brequinar blocked the replication of the virus that causes COVID-19 in lung cells and in mice.
Read the Penn Medicine press release
